Virginia A. Schad, PharmD, RPh

According to a recently published study, a high level of hepatitis B core-related antigen is a complementary risk factor for hepatocellular carcinoma development.

Investigators assessed the diagnostic performance of AST to Platelet Ratio Index and Fibrosis-4 scores compared with transient elastography evaluation of liver stiffness to detect significant fibrosis or cirrhosis.

Researchers found data that showed schistosomiasis does not escalate liver damage in patients who are infected with the hepatitis B virus.

From a nationwide Swedish registry, researchers found data that showed in patients with hepatitis B or C virus infection, the long-term hepatocellular carcinoma risk was lower in patients who were treated with lipophilic statins.

Investigators found data that showed patients with hepatitis C virus infection who had a sustained viral response to treatment with interferon had less incidence of extrahepatic manifestations.

Researchers found data that showed less than 10% of people diagnosed with chronic hepatitis C virus infection received treatment with DAAs.

In China, researchers found data from a small cohort of patients who had undergone liver transplant that showed hepatitis B vaccination was effective in preventing hepatitis B virus reactivation

Researchers found data that showed that after treatment with sofosbuvir plus an NS5A inhibitor in patients with chronic hepatitis C genotype 1, regardless of compensated cirrhosis, a sustained virologic response was achieved in more than 90% of patients after 16 weeks of treatment with glecaprevir/pibrentasvir.

Investigators found data that showed certain factors contributed to reinfection with the hepatitis C virus after treatment with direct-acting antivirals in people who inject drugs.

In US patients aged 20 to 59 years with a history of injection drug use, data showed that the prevalence of previous or ongoing hepatitis B virus infection is 4 times higher than in the general population.

Italian investigators found data that showed bulevirtide combined with tenofovir disoproxil fumarate was found to be well tolerated in patients with hepatitis D virus-related cirrhosis.

Researchers report on use of the short-duration, pangenotypic, ribavirin-free regimen in adolescents with chronic HCV infection.

Researchers found data that suggest after hepatitis C virus clearance impairment of HCV-specific CD8+ T cells persists.

In Spain, researchers found data from a real-world cohort that showed that retreatment and a sustained viral response, depending upon treatment nonresponse and genotype, can be achieved with certain combinations of direct-acting antivirals.

Researchers in Australia found that treatment with direct acting antivirals for hepatitis C in the primary care setting is effective in treatment uptake in people who inject drugs, compared with referrals to hospital-based services.

Researchers found data that showed after liver transplantation in patients with hepatitis C virus, early acute cellular rejection is less common in the direct-acting antiviral era, with reduced mortality.

Researchers found data that showed in patients with hepatitis C, the presence of resistance-associated substitutions did not change the sustained viral response after treatment failure with other direct-acting-antivirals with the combination of sofosbuvir, velpatasvir, and voxilaprevir.

Researchers found data that showed in pregnant women with hepatitis B, the antiviral medications telbivudine and tenofovir disoproxil fumarate were safe, effective, and well tolerated, while reducing transmission of hepatitis B from mother to child during the perinatal period.

Researchers found data that showed sofosbuvir/velpatasvir is safe for the treatment of hepatitis C virus in patients with end-stage renal disease and severe renal impairment.

Researchers found data that showed chronic hepatitis C virus infection and associated carotid intima-media thickness and plaque are predictors for cerebrovascular disease.

In China, researchers found data that showed that patients with HBsAg seropositive test results were at an increased risk of developing hepatocellular carcinoma, stomach cancer, oral cancer, colorectal cancer, pancreatic cancer, and lymphoma.

Researchers found data from that showed the once-daily, direct-acting antiviral regimen, glecaprevir co-formulated with pibrentasvir, is effective and safe in hepatitis C.

US researchers found data that showed participants had a 32% of awareness for hepatitis B infection and 49% were aware of infection with hepatitis C virus.

In Brazil, investigators found that approximately 80% of participants with HIV responded to the hepatitis B virus vaccine, which they believe correlates with a better prognosis and cost effectiveness for treatment.

Researchers found data that showed that in order to eliminate the US health threat of hepatitis C virus within approximately 15 years will require both scaling up medication-assisted treatment and syringe service programs.

Researchers found that hepatitis delta virus endures cell division in vitro and in vivo, which they believe shows a need for the development of antiviral agents that target hepatitis delta virus and reinfection of human hepatocytes.

After expanding, freezing, thawing and re-culturing novel wild-type isolates of hepatitis E, investigators in Europe observed what they categorized as an unlimited production of hepatitis E virus during a period of 2 years, which they believe will allow in vitro testing for the effectiveness of sofosbuvir in combination with ribavirin or silvestrol.

Researchers found data that showed among patients who are HIV positive, hepatitis E viral transmission is unrelated to sexually transmitted disease.

Researchers found data that showed rituximab therapy for rheumatoid arthritis can induce hepatitis B virus in the early phase for patients who have positive test results for the hepatitis b surface antigen and in the late phase for patients with resolved hepatitis B virus infection.

Researchers found data that showed that the baseline hepatitis B core antibody level is indicative of spontaneous hepatitis B e antigen seroconversion in children who were diagnosed as being hepatitis B e antigen-positive, yet untreated, and with normal alanine aminotransferase levels.